Real world data (RWD) and artificial intelligence (AI) offer an unprecedented opportunity for Medical Affairs professionals to gather and share deeper insights about patients, including insights regarding disease progression, outcomes, and treatment response, as well as additional insights about patients’ journeys prior to diagnosis and after treatment initiation. Cindy Weber, of IQVIA’s Artificial Intelligent Solutions team explains how embracing RWD and technology, and the opportunities they provide, is helping to transform Medical Affairs and is enabling professionals to create better, more meaningful, connections with healthcare professionals; thereby helping to improve patient care.
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while AI Proteins has enters a collaboration with Astellas to design novel miniprotein therapeutics.
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
